(Q44381028)

2 December 2017

title

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study (English)

1 reference

non-alcoholic steatohepatitis

2 December 2017

0 references

1 reference

2

1 reference

2 December 2017

Nasser Rakhshani

5

0 references

Masoud Reza Sohrabi

object named as

Masoud Reza Sohrabi

series ordinal

3

0 references

Amir Ali Sohrabpour

series ordinal

6

object named as

Amir Ali Sohrabpour

1 reference

2 December 2017

4

Masoud Sotoudeh

1 reference

2 December 2017

1

Shahin Merat

1 reference

2 December 2017

Siavosh Naserimoghadam

series ordinal

7

object named as

Siavosh Naserimoghadam

1 reference

2 December 2017

publication date

1 April 2003

1 reference

2 December 2017

published in

Journal of Hepatology

1 reference

2 December 2017

volume

38

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

414-418

1 reference

Nonalcoholic Steatohepatitis

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Etiopathogenesis of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Antioxidative properties of probucol estimated by the reactivity with superoxide and by electrochemical oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Treatment of nonalcoholic fatty liver: present and emerging therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Association of nonalcoholic fatty liver disease with insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Metformin reverses fatty liver disease in obese, leptin-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Metformin in non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Phenolic antioxidants: a rationale for design and evaluation of novel antioxidant drug for atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

A novel series of 2,6,7-substituted 2,3-dihydro-1,4-benzodioxin and 2,6,7-substituted 1,4-benzodioxin derivatives as lipid peroxidation inhibitors. Structure-activity relationships for high inhibition of human low-density lipoprotein peroxidation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

Anti-ulcer effects of antioxidants: effect of probucol

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900441-5

7 January 2021

10.1016/S0168-8278(02)00441-5

Identifiers

DOI

1 reference

2 December 2017

1 reference